Artivion, Inc. (NYSE:AORT) Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. lowered its stake in shares of Artivion, Inc. (NYSE:AORT) by 10.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,921 shares of the company’s stock after selling 914 shares during the period. PNC Financial Services Group Inc.’s holdings in Artivion were worth $226,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Quarry LP boosted its stake in Artivion by 210.8% during the third quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after buying an additional 820 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Artivion by 236.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock valued at $32,000 after purchasing an additional 786 shares during the last quarter. R Squared Ltd acquired a new position in shares of Artivion in the 4th quarter valued at $39,000. Arcadia Investment Management Corp MI acquired a new position in shares of Artivion in the 4th quarter valued at $43,000. Finally, Venturi Wealth Management LLC acquired a new position in shares of Artivion in the 4th quarter valued at $78,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Insiders Place Their Bets

In other Artivion news, SVP Jean F. Holloway sold 18,020 shares of the company’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total value of $425,452.20. Following the completion of the transaction, the senior vice president now owns 197,184 shares in the company, valued at $4,655,514.24. This represents a 8.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider John E. Davis sold 15,100 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total value of $356,511.00. Following the completion of the sale, the insider now directly owns 208,778 shares of the company’s stock, valued at approximately $4,929,248.58. This trade represents a 6.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 90,799 shares of company stock worth $2,356,223 in the last 90 days. Corporate insiders own 8.10% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus reduced their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Needham & Company LLC reduced their price target on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Finally, JMP Securities reissued a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a research note on Tuesday, December 10th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $31.40.

Artivion Price Performance

Shares of AORT opened at $24.47 on Friday. Artivion, Inc. has a fifty-two week low of $19.36 and a fifty-two week high of $32.33. The firm’s 50 day moving average price is $28.14 and its 200 day moving average price is $27.64. The company has a market cap of $1.03 billion, a P/E ratio of -1,223.50 and a beta of 1.79. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The firm had revenue of $97.31 million for the quarter, compared to analyst estimates of $100.82 million. On average, research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.